Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01005901 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,324
- Enrollment target
NCT01005901 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,324 participants.
The verdict
NCT01005901, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,324 participants
- Enrollment target
Study Summary
A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Interventions
- DRUG Placebo
- DRUG Glycopyrronium bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,324 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01005901
The ClinicalTrials.gov registry entry for NCT01005901 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,324 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01005901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01005901 about?
NCT01005901 is a clinical study titled "A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo". A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT01005901?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,324 participants. The study started on 2009-10. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01005901?
The interventions under investigation include: Placebo (DRUG), Glycopyrronium bromide (DRUG).
Who is sponsoring clinical trial NCT01005901?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.